Corcept Therapeutics’ Post

🚨 New #DiabetesDialogue! 🚨 Hear from John Buse, MD, PhD, as he discusses why he says the 2-part CATALYST trial might be the "biggest thing that I have ever done in my career" with Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES and Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCES. Get a deep dive into the trial, including part 2, which will examine use of mifepristone (Korlym; Corcept Therapeutics) among patients who screened positive for hypercortisolism. https://lnkd.in/et4uQuDg #Type2Diabetes #Hypercortisolism

Amneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable Medicine A Value-added Stable Presentation where NO Reconstitution, Dilution or Refrigeration requires. https://lnkd.in/gzrGv2Q6 #Amneal #PEMRYDI_RTU

Sharing an in-depth look at the “radiopharma” competitive landscape, courtesy of OPCO. Dive into the latest insights on this potentially impactful modality that is poised to change the standard of care in oncology! #biotech #healthcare #medicine #radiopharma #oncology #cancer

Joint Clinical Assessment (JCA) is a central component of the new European Union health technology assessment (EU HTA) Regulation, which will streamline HTA across EU member states and play a major role in bringing new medical technology to market. In our whitepaper Lumanity experts explore the challenges of JCA, with particular focus on oncology, rare disease and advanced therapy medicinal products (ATMPs). https://buff.ly/45mgJE6 #LumanityPerspectives #HTA #JCA #HEOR #EUHTA

#PRECLINICAL RESEARCHERS in Idiopathic Pulmonary Fibrosis (#IPF) - MLM's highly refined and optimized IPF Preclinical Model will significantly accelerate the future discovery of innovative therapies for IPF patients. Learn more https://lnkd.in/gsBchHBF #preclinicalmodel #IPFmodel #preclinicalresearch

Joint Clinical Assessment (JCA) is a central component of the new European Union health technology assessment (EU HTA) Regulation, which will streamline HTA across EU member states and play a major role in bringing new medical technology to market. In our whitepaper Lumanity experts explore the challenges of JCA, with particular focus on oncology, rare disease and advanced therapy medicinal products (ATMPs). https://buff.ly/3YQtCF5 #LumanityPerspectives #HTA #JCA #HEOR #EUHTA

INDUSTRY NEWS - CAR-T in autoimmunity My thoughts on the news 'Cartesian Therapeutics clears an autoimmune CAR-T trial, starts another Phase 2 and raises $130M' https://lnkd.in/eHtpW7T3 This is an exciting development that expands on tantalizing CAR-T data in autoimmunity first reported in lupus last year. Is autoimmunity the saving grace for the CAR-T field as multiple companies migrate from oncology? The competition will be no less fierce in autoimmunity where mAbs have made significant advances over the years and are truly off-the-shelf products, and cheaper as well. One key question concerns how many CAR-T products can the autoimmunity field accommodate, especially if they are all targeting B cell specific antigens. Perhaps the competitive landscape will be adjudicated by the relative durability of any response. Whereas the durability of mAb function is dictated by standard pharmacokinetics, the durability of CAR-T responses may be longer if they function as an immunomodulatory reset to the immune system. Time and data will tell. #Alloplex #celltherapies #CAR-T #oncologyresearch #cancerresearch

Today, we are sharing our CEOs thoughts on a recent exciting industry development

We launched our latest Special Report! Hear from Palak Trivedi, MD, PhD, University of Birmingham, and Boyer James, MD, of Yale School of Medicine, as they discuss the rapidly changing landscape of primary biliary cholangitis. In the video below, the pair discuss recent therapeutic advancements in PBC, including new treatments like elafibranor (Iqirvo; Ipsen) and the anticipated approval of seladelpar (CymaBay Therapeutics). Use the link to view the full, 5-part video series: https://lnkd.in/etSNE8Dw #Hepatology

Progentos Therapeutics Secures $65 Million Series A To Advance MS Treatment Learn more & get our take 👇 https://lnkd.in/gQjEwDh9 “While there are many treatments that are highly effective at slowing the progression of disease, there is a significant unmet need for new approaches that can regenerate myelin and restore function for patients with MS,” – Dr. Chris Loose, PhD, CEO at Progentos “We are truly excited to be part of Progentos’ journey towards delivering potentially disease-modifying drugs for diseases like multiple sclerosis, diseases with high unmet clinical needs,” – Dr. Dmitrij Hristodorov, Ph.D., General Partner at Forbion #funding #mstreatment #SoHCNews